Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.
Press releases published on September 4, 2025
Cancer Focus Fund Appoints Distinguished Industry Experts David R. Epstein and Michael Margolis as Advisors to Its Investment Committee
GlobeNewswire
·
September 4, 2025
—Epstein and Margolis Bring Decades of Business Expertise and Industry Leadership to Cancer Focus Fund as It Prepares for Its Next Round of Investments— HOUSTON, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Cancer Focus Fund, LP, a unique investment fund established …
BPGbio Announces Completion of Enrollment for Phase 2b Trial of BPM31510 for Glioblastoma (GBM)
GlobeNewswire
·
September 4, 2025
Topline Phase 2b Clinical Data Expected in 1H 2026 Trial-in-Progress Presentations Scheduled for ESMO and SNO in Fall 2025 BPM31510 has Received Orphan Drug Designation from the U.S. FDA for the Treatment of GBM BOSTON, Sept. 04, 2025 (GLOBE NEWSWIRE) -- …
BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 4, 2025
NEW HAVEN, Conn., Sept. 04, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that Vimal Mehta, Ph.D., CEO …
Algernon Pharmaceuticals Announces Name Change to Algernon Health
GlobeNewswire
·
September 4, 2025
VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company announces that it is changing its name to Algernon Health …
Skye’s CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model
GlobeNewswire
·
September 4, 2025
Skye shares new preclinical DIO data at virtual KOL event Nimacimab + tirzepatide demonstrates over 40% weight loss in multiple preclinical DIO studies Nimacimab demonstrates durable post-treatment weight loss compared to tirzepatide Nimacimab reduced …
Join XORTX for an Exclusive Live Investor Webinar and Q&A Session on September 10
GlobeNewswire
·
September 4, 2025
CALGARY, Alberta, Sept. 04, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and …
Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia
GlobeNewswire
·
September 4, 2025
PDUFA goal date extended by three months from September 7, 2025, to December 7, 2025 CAMBRIDGE, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering …
GT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 4, 2025
The Company is available for one-on-one meetings at the H.C. Wainwright Conference September 8-10, 2025 in New York City Phase 1 trial evaluating GTBP-3650 for the treatment of relapsed or refractory (r/r) CD33 expressing hematologic malignancies continues …
Sol-Gel Announces Health Canada Approval of EPSOLAY®
GlobeNewswire
·
September 4, 2025
NESS ZIONA, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (patidegib gel, 2%) for …
Merakris Therapeutics Enrolls 30th Subject in Expanded Access Program of MTX-001; Highlights Clinical Progress at SAWC Fall 2025
GlobeNewswire
·
September 4, 2025
RESEARCH TRIANGLE PARK, N.C, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics, a regenerative medicine company developing biologically derived therapeutics, announced the enrollment of the 30th subject in its Expanded Access Program (EAP) of MTX- …
ITM to Present at the Oppenheimer Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
GlobeNewswire
·
September 4, 2025
Garching / Munich, Germany, September 4, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in the Oppenheimer Annual Targeted Radiopharmaceutical Therapies in Oncology Summit …
Rakovina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 4, 2025
VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, today announced …
AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway
GlobeNewswire
·
September 4, 2025
AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway Strategic review by executive management yields increased pipeline focus and operational efficiencies with a workforce reduction of around 30% Increased emphasis on late- …
Lygos Clinic Launches VIP All-Inclusive Dental Tourism Packages for International Patients
GlobeNewswire
·
September 4, 2025
ISTANBUL, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lygos Clinic, a leading dental center in Istanbul, has officially launched its new VIP all-inclusive dental tourism packages, designed to meet the rising global demand for premium, affordable cosmetic dentistry. …
Onco3R Therapeutics Announces Approval of First Clinical Trial Application for Novel SIK3 inhibitor O3R-5671 in Autoimmune Diseases
GlobeNewswire
·
September 4, 2025
O3R-5671 is designed to overcome the limitations of first-generation SIK inhibitors, providing a potential new oral treatment option for multiple autoimmune diseases Clinical Trial Application approval marks Onco3R’s transition into a clinical-stage …
PulseSight Therapeutics Provides New Insights into the Role of Iron and Transferrin in AMD, Supporting its PST-611 Vectorized Therapy for Dry AMD/Geographic Atrophy at EURETINA 2025
GlobeNewswire
·
September 4, 2025
PARIS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology announces that its CSO, Thierry Bordet Ph.D., will present …
Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders
GlobeNewswire
·
September 4, 2025
MINNEAPOLIS and BRISBANE, Australia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting- …
Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed
GlobeNewswire
·
September 4, 2025
Company expects to fully repay existing financial debts in 2026 NCX 470 NDA submissions in U.S. (H1 2026) and subsequently in China Milestones payable on U.S. NDA submission and on approval Glaukos extends NCX 1728 research agreement Future strategic …
Nicox prévoit de rembourser intégralement ses dettes financières, NCX 470 ayant été dé-risqué et licencié dans le monde entier
GlobeNewswire
·
September 4, 2025
4 septembre 2025 – publication à 7H30 Sophia Antipolis, France Nicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), une société internationale spécialisée en ophtalmologie, annonce aujourd’hui qu’elle prévoit de rembourser l’ …
Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
GlobeNewswire
·
September 4, 2025
Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis Amlitelimab, dosed every four weeks or every 12 weeks, demonstrated statistically significant and clinically …